| 蒙茜,孙洪福,黄伟.肿瘤免疫治疗相关PD-(L)1 PET靶向核素探针应用研究进展[J].中华放射医学与防护杂志,2024,44(2):158-162 |
| 肿瘤免疫治疗相关PD-(L)1 PET靶向核素探针应用研究进展 |
| Progress in the application of PD-(L)1 PET-targeted nuclide probes for tumor immunotherapy-related studies |
| 投稿时间：2023-07-03 |
| DOI：10.3760/cma.j.cn112271-20230703-00223 |
| 中文关键词: 程序性细胞死亡分子-1/配体-1 分子成像 正电子发射型计算机断层显像示踪剂 免疫治疗 |
| 英文关键词:programmed death receptor-1/programmed death receptor-ligand 1 Molecular imaging Positron emission computed tomography tracer Immunotherapy |
| 基金项目: |
|
| 摘要点击次数: 556 |
| 全文下载次数: 155 |
| 中文摘要: |
| 免疫治疗已经进入多种肿瘤的临床治疗。程序性细胞死亡分子-1/配体-1(PD-1/PD-L1)免疫检查点的阻断治疗是目前最重要的肿瘤免疫治疗方法。目前临床上通过免疫组织化学方法(IHC)检测肿瘤患者PD-L1表达情况并筛选适应证,但PD-L1表达异质性、动态变化性以及样本取材受限等因素限制了经此法对肿瘤患者体内PD-L1表达情况的评估价值。 PD-(L)1 PET成像利用放射性标记分子在空间和时间上非侵入性地评估 PD-(L)1 的表达,和免疫组织化学互补使用,理论上存在不可比拟的优势。本文就 PD-(L)1 探针分子成像原理、临床研究及存在问题等最新进展做一综述。 |
| 英文摘要: |
| Immunotherapy has entered the clinical treatment for various tumors, among which the blockade therapy of PD-1/PD-L1 immune checkpoint is currently the most important tumor immunotherapy method. At present, immunohistochemical method are used in clinical practice to detect PD-L1 expression in tumor patients and screen for indications. However, this method is constrained by factors such as heterogeneity, dynamic changes in PD-L1 expression, and limited sample collection. PD-(L)1 PET imaging utilizes radiolabeled molecules to non-invasively assess PD-(L)1 expression in space and time, and complementary use with IHC has theoretically incomparable advantages. This article reviews the latest progress in the PD-(L)1 probe molecular imaging principles, clinical research and existing problems. |
| HTML 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |